» Articles » PMID: 23107591

Randomized Comparative Study of the Serum Antihemagglutinin and Antineuraminidase Antibody Responses to Six Licensed Trivalent Influenza Vaccines

Overview
Journal Vaccine
Date 2012 Oct 31
PMID 23107591
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Serum antibody to the hemagglutinin (HA) surface protein of influenza virus induced by influenza vaccination is a correlate of protection against influenza. The neuraminidase (NA) protein is also on the surface of the virus; antibody to it has been shown to impair virus release from infected cells and to reduce the intensity of influenza infections in animal models and in humans challenged with infectious virus. Recently we have shown that NA inhibiting antibody can independently contribute to immunity to naturally-occurring influenza immunity in the presence of antibody to the HA.

Purpose: The present study was conducted to evaluate induction of antibody to the NA and the HA by commercially available influenza vaccines.

Methods: Healthy young adults were vaccinated with one of five commercially available trivalent inactivated vaccines or live influenza vaccine. Frequencies of serum antibody and fold geometric mean titer (GMT) increases four weeks later were measured to each of the three vaccine viruses (A/H1N1, A/H3N2, B) in hemagglutination-inhibition (HAI) and neutralization (neut) assays. Frequency and fold GMT increase in neuraminidase-inhibition (NI) antibody titers were measured to the influenza A viruses (A/H1N1, A/H3N2).

Results: No significant reactogenicity occurred among the vaccinated subjects. The Fluvirin inactivated vaccine induced more anti-HA antibody responses and a higher fold GMT increase than the other inactivated vaccines but there were no major differences in response frequencies or fold GMT increase among the inactivated vaccines. Both the frequency of antibody increase and fold GMT increase were significantly lower for live vaccine than for any inactivated vaccine in HAI and neut assays for all three vaccine viruses. Afluria inactivated vaccine induced more N1 antibody and Fluarix induced more N2 antibody than the other vaccines but all inactivated vaccines induced serum NI antibody. The live vaccine failed to elicit any NI responses for the N2 NA of A/H3N2 virus and frequencies were low for the N1 of A/H1N1 virus.

Conclusions: Trivalent inactivated influenza vaccines with similar HA dosage induce similar serum anti-HA antibody responses in healthy adults. Current inactivated vaccines all induce serum anti-NA antibody to the N1 and N2 NA proteins but some are better than others for N1 or N2. The live vaccine, Flumist, was a poor inducer of either anti-HA or anti-NA serum antibody compared to inactivated vaccine in the healthy adults. In view of the capacity for contributing to immunity to influenza in humans, developing guidelines for NA content and induction of NA antibody is desirable.

Citing Articles

Expert consensus on the benefits of neuraminidase in conventional influenza vaccines: a Delphi study.

Youhanna J, Puig-Barbera J, Miller M, Molrine D, Hadi M, Bapat S BMC Infect Dis. 2025; 25(1):53.

PMID: 39794704 PMC: 11724539. DOI: 10.1186/s12879-024-10277-4.


Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA.

Leonard R, Burke K, Spreng R, Macintyre A, Tam Y, Alameh M Nat Commun. 2024; 15(1):8712.

PMID: 39379405 PMC: 11461824. DOI: 10.1038/s41467-024-52940-z.


COBRA N2 NA vaccines induce protective immune responses against influenza viral infection.

Zhang X, Skarlupka A, Shi H, Ross T Hum Vaccin Immunother. 2024; 20(1):2403175.

PMID: 39291424 PMC: 11657087. DOI: 10.1080/21645515.2024.2403175.


Antibody-independent surface plasmon resonance assays for influenza vaccine quality control.

Serafin B, Kamen A, De Crescenzo G, Henry O Appl Microbiol Biotechnol. 2024; 108(1):307.

PMID: 38656587 PMC: 11043112. DOI: 10.1007/s00253-024-13145-y.


Anti-neuraminidase immunity in the combat against influenza.

Zhang X, Ross T Expert Rev Vaccines. 2024; 23(1):474-484.

PMID: 38632930 PMC: 11157429. DOI: 10.1080/14760584.2024.2343689.


References
1.
La Montagne J, Noble G, Quinnan G, Curlin G, Blackwelder W, Smith J . Summary of clinical trials of inactivated influenza vaccine - 1978. Rev Infect Dis. 1983; 5(4):723-36. DOI: 10.1093/clinids/5.4.723. View

2.
Fleming D, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A . Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006; 25(10):860-9. DOI: 10.1097/01.inf.0000237797.14283.cf. View

3.
SCHULMAN J, Khakpour M, KILBOURNE E . Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol. 1968; 2(8):778-86. PMC: 375691. DOI: 10.1128/JVI.2.8.778-786.1968. View

4.
Ashkenazi S, Vertruyen A, Aristegui J, Esposito S, McKeith D, Klemola T . Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J. 2006; 25(10):870-9. DOI: 10.1097/01.inf.0000237829.66310.85. View

5.
Fiore A, Uyeki T, Broder K, Finelli L, Euler G, Singleton J . Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010; 59(RR-8):1-62. View